%0 Systematic Review
%T Ibrutinib and tracheal mucormycosis: A case report and systematic review of literature.
%A Damaraju V
%A Agarwal R
%A Singh Sehgal I
%A Khadwal A
%A Bal A
%A Rudramurthy SM
%A Muthu V
%J J Mycol Med
%V 33
%N 3
%D 2023 Aug 23
%M 37523991
%F 3.746
%R 10.1016/j.mycmed.2023.101414
%X Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has been approved for various hematological malignancies. Invasive aspergillosis is a known complication of ibrutinib, but mucormycosis is rare. We describe the case of a 70-year-old man with mantle cell lymphoma infiltrating the trachea, managed with a tracheobronchial stent and ibrutinib. He had improved one month after treatment, and we removed the airway stent. Four months later, he developed tracheal nodules confirmed to be tracheal mucormycosis and responded to liposomal amphotericin B (3.5 g) followed by posaconazole. After transient improvement, the tracheal lesions recurred, the biopsy showed lymphoma (with no evidence of mucormycosis), and he died. A systematic review of the literature identified 20 additional cases of ibrutinib-associated mucormycosis. Most of the 21 patients included were men (95%), and ibrutinib was the only risk factor in 15.7%. The reported mortality was 31.6% (6/19), attributable to mucormycosis in half the cases.